Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00313235
Other study ID # Baylor IRB #006-025-01
Secondary ID IND 12919
Status Completed
Phase Phase 1/Phase 2
First received April 10, 2006
Last updated June 12, 2013
Start date March 2006
Est. completion date June 2012

Study information

Verified date June 2013
Source Baylor Research Institute
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test a combined treatment using cyclophosphamide and a novel dendritic cell vaccine in patients with Stage IV melanoma.


Description:

A novel dendritic cell vaccine is being developed at the Baylor Institute for Immunology Research. Pre-clinical studies have found that this dendritic cell vaccine is more efficient in inducing a tumor specific immunity than other dendritic cell vaccines. Further studies in BIIR have been done with dendritic cells that were loaded with killed melanoma cells from a melanoma cell line treated with heat before loading. Both studies have shown that DCs manufactured in this novel way were more efficient in priming the melanoma specific CD8+ cells. Our previous studies indicate that a portion of patients with stage IV melanoma cannot mount an immune response to tumor antigens presented on dendritic cells. Also, regulatory/suppressor T cells can be identified in the blood of these patients, which may account for the lack of induction of T cell immunity to dendritic cell vaccines. Cyclophosphamide treatments have improved antitumor immunity in humans with melanoma and a clear relationship between cyclophosphamide dosage and suppressor cell activity has been documented. Therefore, this trial will test a combined modality treatment, using dendritic cell based vaccines in patients who have been treated with cyclophosphamide.

This clinical trial will evaluate the cyclophosphamide/dendritic cell vaccine in patients with Stage IV melanoma. The trial will accrue a total of 33 subjects. The primary goal of this trial will be to test the safety/tolerability/feasibility of the combined modality and the rate of objective clinical response.However if feasibility data in the first 10 subjects demonstrate the need to adjust the dose of CPA, the new dose will be tested in the next 10 subjects thereby extending the accrual to 43 subjects. A 15% objective response rate will be accepted in patients with stage IV Melanoma.

Patients will receive cyclophosphamide 300 mg/m2, administered 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Each subject will initially receive 7 doses of vaccination with each individual dose being administered at weeks 0, 2, 4, 6, 10, 14 and 18. A clinical evaluation of the patients will be done at weeks 10 & 20. Patients with progressive disease will be taken off of the study. Patients with SD, PR or CD (according to RECIST criteria) may receive 4 more vaccinations. Scans and re-staging tests will be performed at scheduled intervals throughout the study.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date June 2012
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender Both
Age group 21 Years to 75 Years
Eligibility Inclusion Criteria:

- Stage M1a, M1b, M1c biopsy proven metastatic melanoma.

- Ages 21-75.

- Karnofsky performance status greater than/equal to 80%.

- Measurable metastatic lesions by physical exam or scans.

- Acceptable CBC and blood chemistry results.

- Adequate hepatic and renal function.

- No active CNS metastatic disease. If CNS history is present, lesions must have been resected by surgery and/or gamma knife irradiation at least 3 months prior to study entry. The total number of CNS lesions at diagnosis should not exceed 3.

- Written informed consent.

Exclusion Criteria:

- Patients that have received more than 8 cycles of chemotherapy for metastatic melanoma.

- Patients who have received chemotherapy less than 4 weeks before beginning the trial.

- Patients who have received IFN alpha-2b or GM-CSF less than 4 weeks before beginning the trial.

- Patients who have received high-dose IL-2 less than 4 weeks before beginning the trial.

- Patients diagnosed with more than 3 CNS metastatic melanoma lesions.

- More than 5 hepatic lesions or any hepatic lesion larger than 5 cm.

- Baseline serum LDH greater than 1.1 times the upper limit of normal.

- Patients who are HIV positive.

- Patients who are pregnant.

- Patients who have receive corticosteroids or other agents less than 4 weeks before beginning the trial.

- Patients with asthma, angina pectoris or congestive heart failure.

- Patients with autoimmune disease such as lupus erythematosus, rheumatoid arthritis or thyroiditis.

- Patients with active infections including viral hepatitis.

- Patients with a history of any other neoplastic disease less than 5 years ago (carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin, however, can be admitted to the study).

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
DC Vaccine and Cyclophosphamide
Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site). Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks. CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure.

Locations

Country Name City State
United States Baylor University Medical Center Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
Baylor Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of the combination of DC vaccination and CPA therapy in human subjects 2 Years Yes
Primary Feasibility of this combination therapy 2 Years Yes
Primary Objective clinical responses 2 Years No
Secondary Immunogenicity of DC vaccinations in subjects 2 Years No
Secondary Effect of CPA at this dose and schedule on the regulatory/suppressor T cells 2 years No
See also
  Status Clinical Trial Phase
Recruiting NCT03132090 - Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI N/A
Completed NCT01676779 - mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma Phase 2
Terminated NCT04577729 - The IRMI-FMT Trial N/A
Completed NCT02439411 - Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
Recruiting NCT03166397 - Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Phase 2
Not yet recruiting NCT05304546 - Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Phase 2
Terminated NCT00722098 - Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients Phase 2
Terminated NCT03430947 - Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases Phase 2
Completed NCT01189383 - IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma Phase 1/Phase 2
Completed NCT01983124 - Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib Phase 2
Completed NCT01302496 - Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma Phase 2
Not yet recruiting NCT03493230 - Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) N/A